公开(公告)号：US09492449B2

公开(公告)日：2016-11-15

申请号：US13417185

申请日：2012-03-09

Applicant: W. Michael Gallatin ,  Roger G. Ulrich ,  Neill A. Giese ,  Brian Lannutti ,  Langdon Miller ,  Thomas M. Jahn

Inventor： W. Michael Gallatin ,  Roger G. Ulrich ,  Neill A. Giese ,  Brian Lannutti ,  Langdon Miller ,  Thomas M. Jahn

IPC: A61K31/517 ,  A61K31/395 ,  A61K31/519 ,  A61K39/00

CPC classification number: A61K31/52 ,  A61K31/495 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/69 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505

Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R′ is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.

公开(公告)号：US09226919B2

公开(公告)日：2016-01-05

申请号：US11974068

申请日：2007-10-11

Applicant: Samit Hirawat ,  Langdon Miller

Inventor： Samit Hirawat ,  Langdon Miller

IPC: A61K31/4245

CPC classification number: A61K31/4245 ,  A61K9/0095 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

Abstract translation: 本发明涉及使用1,2,4-恶二唑苯甲酸化合物治疗或预防与无义突变有关的疾病的具体剂量和给药方案。 特别地，本发明涉及在具有相关疾病的哺乳动物中使用3- [5-（2-氟 - 苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的具体剂量和给药方案 具有无义突变。

公开(公告)号：US20120157402A1

公开(公告)日：2012-06-21

申请号：US13321252

申请日：2010-05-27

Applicant: Liangxian Cao ,  Thomas W. Davis ,  Samit Hirawat ,  Harry H. Miao ,  langdon Miller ,  Marla Weetall

Inventor： Liangxian Cao ,  Thomas W. Davis ,  Samit Hirawat ,  Harry H. Miao ,  langdon Miller ,  Marla Weetall

IPC: A61K31/437 ,  A61K31/496 ,  A61K31/541 ,  A61P35/00 ,  A61K31/695 ,  A61K31/706 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/53

CPC classification number: A61K31/437

Abstract: Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Abstract translation: 描述了治疗涉及施用选择性抑制人VEGF病理生成的化合物的脑肿瘤的方法。 该化合物可以作为单一药物治疗或与需要这种治疗的人的一种或多种另外的治疗组合施用。

公开(公告)号：US08076352B2

公开(公告)日：2011-12-13

申请号：US11735069

申请日：2007-04-13

Applicant: Liangxian Cao ,  Samit Hirawat ,  Langdon Miller ,  Thomas Davis ,  Marla L. Weetall

Inventor： Liangxian Cao ,  Samit Hirawat ,  Langdon Miller ,  Thomas Davis ,  Marla L. Weetall

IPC: A61K31/437 ,  C07D487/04

CPC classification number: A61K31/437 ,  A61K31/4353 ,  A61K31/444 ,  A61K31/5377

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing serum, plasma, and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Abstract translation: 根据本发明，已经鉴定了抑制转录后VEGF表达的化合物，以及这些化合物的给药和使用的组合物和方法。 提供。 在本发明的一个方面，提供了可用于抑制VEGF产生，治疗实体瘤癌症和降低血清，血浆和/或肿瘤VEGF水平的化合物。 在本发明的另一方面，提供了使用本发明化合物抑制VEGF产生，治疗癌症以及降低血浆和/或肿瘤VEGF水平的方法。

公开(公告)号：US20070254878A1

公开(公告)日：2007-11-01

申请号：US11735069

申请日：2007-04-13

Applicant: Liangxian Cao ,  Samit Hirawat ,  Langdon Miller ,  Gary Elfring

Inventor： Liangxian Cao ,  Samit Hirawat ,  Langdon Miller ,  Gary Elfring

IPC: A61K31/4353 ,  A61K31/444 ,  A61K31/5377 ,  A61P35/00

CPC classification number: A61K31/437 ,  A61K31/4353 ,  A61K31/444 ,  A61K31/5377

Abstract: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing serum, plasma, and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Abstract translation: 根据本发明，已经鉴定了抑制转录后VEGF表达的化合物，以及这些化合物的给药和使用的组合物和方法。 提供。 在本发明的一个方面，提供了可用于抑制VEGF产生，治疗实体瘤癌症和降低血清，血浆和/或肿瘤VEGF水平的化合物。 在本发明的另一方面，提供了使用本发明化合物抑制VEGF产生，治疗癌症以及降低血浆和/或肿瘤VEGF水平的方法。

公开(公告)号：US08716321B2

公开(公告)日：2014-05-06

申请号：US11918114

申请日：2006-04-06

Applicant: Samit Hirawat ,  Langdon Miller

Inventor： Samit Hirawat ,  Langdon Miller

IPC: A61K31/4245 ,  A61P3/10 ,  A61P7/00 ,  A61P9/00 ,  A61P11/00 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00

CPC classification number: A61K31/4245 ,  A61K9/0053 ,  A61K9/145

Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

Abstract translation: 本发明涉及使用1,2,4-恶二唑苯甲酸化合物治疗或预防与无义突变有关的疾病的具体剂量和给药方案。 特别地，本发明涉及在具有相关疾病的哺乳动物中使用3- [5-（2-氟 - 苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的具体剂量和给药方案 具有无义突变。

公开(公告)号：US20120157401A1

公开(公告)日：2012-06-21

申请号：US13321242

申请日：2010-05-27

Applicant: Liangxian Cao ,  Thomas W. Davis ,  Harry H. Miao ,  Langdon Miller ,  Marla Weetall

Inventor： Liangxian Cao ,  Thomas W. Davis ,  Harry H. Miao ,  Langdon Miller ,  Marla Weetall

IPC: A61K31/437 ,  A61K31/496 ,  A61K31/541 ,  A61P25/00 ,  A61K31/506 ,  A61K31/695 ,  A61K31/706 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/53

CPC classification number: A61K31/437

Abstract: Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Abstract translation: 描述了治疗涉及施用选择性抑制人VEGF病理生成的化合物的神经纤维瘤病的方法。 化合物可以作为单一药物治疗或与一种或多种另外的治疗组合施用于需要这种治疗的人。

公开(公告)号：US20090149513A1

公开(公告)日：2009-06-11

申请号：US11918114

申请日：2006-04-06

Applicant: Samit Hirawat ,  Langdon Miller

Inventor： Samit Hirawat ,  Langdon Miller

IPC: A61K31/4245 ,  A61P3/10 ,  A61P7/00 ,  A61P9/00 ,  A61P11/00 ,  A61P25/00 ,  A61P25/28 ,  A61P35/00

CPC classification number: A61K31/4245 ,  A61K9/0053 ,  A61K9/145

Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

Abstract translation: 本发明涉及使用1,2,4-恶二唑苯甲酸化合物治疗或预防与无义突变有关的疾病的具体剂量和给药方案。 特别地，本发明涉及在具有相关疾病的哺乳动物中使用3- [5-（2-氟 - 苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的具体剂量和给药方案 具有无义突变。

公开(公告)号：US20080114039A1

公开(公告)日：2008-05-15

申请号：US11974068

申请日：2007-10-11

Applicant: Samit Hirawat ,  Langdon Miller

Inventor： Samit Hirawat ,  Langdon Miller

IPC: A61K31/4245

CPC classification number: A61K31/4245 ,  A61K9/0095 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

Abstract translation: 本发明涉及使用1,2,4-恶二唑苯甲酸化合物治疗或预防与无义突变有关的疾病的具体剂量和给药方案。 特别地，本发明涉及在具有相关疾病的哺乳动物中使用3- [5-（2-氟 - 苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的具体剂量和给药方案 具有无义突变。

公开(公告)号：US09351964B2

公开(公告)日：2016-05-31

申请号：US13321257

申请日：2010-05-27

Applicant: Neil Almstead ,  Tamil Arasu ,  Soongyu Choi ,  Liangxian Cao ,  Jeffrey Allen Campbell ,  Donald Corson ,  Thomas W. Davis ,  Jason D. Graci ,  Zhengxian Gu ,  Peter Seongwoo Hwang ,  William Lennox ,  Harry H. Miao ,  Langdon Miller ,  Young-Choon Moon ,  Hongyan Qi ,  Christopher Trotta ,  Marla L. Weetall

Inventor： Neil Almstead ,  Tamil Arasu ,  Soongyu Choi ,  Liangxian Cao ,  Jeffrey Allen Campbell ,  Donald Corson ,  Thomas W. Davis ,  Jason D. Graci ,  Zhengxian Gu ,  Peter Seongwoo Hwang ,  William Lennox ,  Harry H. Miao ,  Langdon Miller ,  Young-Choon Moon ,  Hongyan Qi ,  Christopher Trotta ,  Marla L. Weetall

IPC: A01N43/04 ,  A61K31/44 ,  A61K45/06 ,  A61K31/4745 ,  A61K31/437 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4745 ,  A61K45/06 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/401 ,  Y02A50/463 ,  Y02A50/465

Abstract: Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

Abstract translation: 描述了选择性抑制人血管内皮生长因子（VEGF）的病理生成的化合物，例如式（I）的化合物和包含这些化合物的组合物。 描述了抑制病毒复制或产生病毒RNA或DNA或病毒蛋白的化合物和包含这些化合物的组合物。 还描述了使用这些化合物还原VEGF的方法以及用于治疗涉及施用这些化合物的癌症和非肿瘤性病症的方法。 进一步描述的是使用这种用于治疗涉及施用这些化合物的病毒感染的化合物和方法来抑制病毒复制或产生病毒RNA或DNA或病毒蛋白质的方法。 化合物可以作为单一药物治疗或与一种或多种另外的治疗组合施用于需要这种治疗的人。